Mitochondria
and Disease

Read More

Heart Disease: "Deadliest Disease
Known to Man"

Read More

Mitochondrial
Therapies

Read More

Stealth Peptides is a privately held, clinical stage, biopharmaceutical company developing novel and innovative mitochondrial targeted therapies for diseases with clear unmet medical needs including cardiovascular, renal, ophthalmologic, neurologic and metabolic conditions. Stealth Peptides’ first clinical candidate is Bendavia™.

 

Stealth Peptides is initiating a multinational Phase II clinical trial with Bendavia focused on ischemia reperfusion injury in patients experiencing acute ST-segment elevation myocardial infarction (STEMI). The Phase II clinical trial is termed EMBRACE-STEMI™ for the Evaluation of the Myocardial effects of Bendavia for reducing Reperfusion injury in patients with Acute Coronary Events — ST-wave Elevation Myocardial Infarction.